Bayer Investor Relations

Team having a chat
Investor News
Share Price / Index
December 02, 2025
Bayer welcomes Solicitor General support for U.S. Supreme Court review
November 23, 2025
Bayer’s FXIa inhibitor Met Primary Efficacy and Safety Endpoints in Landmark Phase III Study in Secondary Stroke Prevention
November 20, 2025
Not intended for U.S. and UK Media
Accelerated approval in the U.S. for new treatment for patients with previously treated advanced HER2-mutant non-small cell lung cancer